Brokerages Set OPKO Health, Inc. (NASDAQ:OPK) PT at $1.55

OPKO Health, Inc. (NASDAQ:OPK) has been given a consensus rating of “Reduce” by the five brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $1.55.

Several equities research analysts recently weighed in on the stock. Weiss Ratings upgraded shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Finally, Barrington Research downgraded OPKO Health from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 29th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Comerica Bank grew its position in shares of OPKO Health by 7.1% during the 4th quarter. Comerica Bank now owns 120,000 shares of the biotechnology company’s stock worth $151,000 after buying an additional 8,000 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of OPKO Health by 4.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 198,148 shares of the biotechnology company’s stock valued at $262,000 after acquiring an additional 8,954 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of OPKO Health by 11.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 138,643 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 13,912 shares during the period. Intech Investment Management LLC boosted its stake in OPKO Health by 11.4% during the 4th quarter. Intech Investment Management LLC now owns 159,652 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 16,329 shares during the last quarter. Finally, Swiss Life Asset Management Ltd bought a new position in OPKO Health during the 3rd quarter worth approximately $30,000. 64.63% of the stock is currently owned by institutional investors.

OPKO Health Stock Performance

OPKO Health stock opened at $1.22 on Monday. The firm has a market capitalization of $921.21 million, a price-to-earnings ratio of -4.52 and a beta of 1.48. The company has a 50 day moving average price of $1.37 and a 200 day moving average price of $1.26. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.17 and a current ratio of 3.61. OPKO Health has a 52 week low of $0.98 and a 52 week high of $1.61.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $124.20 million during the quarter, compared to analyst estimates of $130.51 million. OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. The company’s revenue for the quarter was down 17.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.10) EPS. Research analysts forecast that OPKO Health will post -0.29 EPS for the current year.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.